Nextstellis is owned by Mayne Pharma.
Nextstellis contains Drospirenone; Estetrol.
Nextstellis has a total of 1 drug patent out of which 0 drug patents have expired.
Nextstellis was authorised for market use on 15 April, 2021.
Nextstellis is available in tablet;oral dosage forms.
Nextstellis can be used as use by females of reproductive potential to prevent pregnancy.
Drug patent challenges can be filed against Nextstellis from April, 2025.
The generics of Nextstellis are possible to be released after 15 April, 2026.
|Patent Number||Company||Patent Title||Patent Expiry||Activity Alert|
|These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).|
|US7732430||MAYNE PHARMA||Drug delivery system comprising a tetrahydroxilated estrogen for use in hormonal contraception|| |
(2 years from now)
|New Chemical Entity Exclusivity (NCE)||Apr 15, 2026|
NCE-1 date: April, 2025
Market Authorisation Date: 15 April, 2021
Treatment: Use by females of reproductive potential to prevent pregnancy
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic